SSY Group Limited (LJUIF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 15.05 means the share price is 15.05 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.19B is the value of all shares combined. Beta 0.49: the stock has moved about 51% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSSY Group Limited (LJUIF) trades at $0.4026. SSY Group Limited researches, develops, manufactures, and sells pharmaceutical products, including intravenous infusion solutions and injections, primarily in China. Market cap: $1.19B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for LJUIF: LJUIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LJUIF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
LJUIF: 2/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
SSY Group Limited (LJUIF) Healthcare & Pipeline Overview
SSY Group Limited is a pharmaceutical company focused on developing, manufacturing, and distributing intravenous infusion solutions, injections, and other pharmaceutical products in China and internationally, with a strong emphasis on the Chinese market and a diverse product portfolio under the Shimen brand.
What Is the Investment Thesis for LJUIF?
With a P/E ratio of 15.05 and a profit margin of 14.4%, the company demonstrates profitability and reasonable valuation. A dividend yield of 5.75% offers an attractive income stream for investors. Growth catalysts include expanding its market share within China and increasing international sales. However, investors may want to evaluate risks associated with regulatory changes in the pharmaceutical industry and competition from both domestic and international players. The company's beta of 0.49 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
LJUIF Key Highlights
Market capitalization of $1.19B, reflecting its significant presence in the pharmaceutical sector.
- P/E ratio of 15.05, indicating a potentially undervalued stock compared to its earnings.
- Profit margin of 14.4%, demonstrating efficient operations and profitability.
- Gross margin of 42.7%, suggesting strong pricing power and cost management.
- Dividend yield of 5.75%, offering an attractive income stream for investors.
Who Are LJUIF's Competitors?
LJUIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BIOGY BioGaia AB (publ) | $12.45 | 0.00% | $1.26B | — |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $0.16 | 0.00% | $821M | — |
| EVOTF Evotec SE | $6.69 | 0.00% | $1.19B | — |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $0.78 | 0.00% | $761M | 529-signal |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $25.77 | 0.00% | $1.07B | — |
| CRON Cronos Group Inc. | $3.16 | +0.16% | $1.18B | 905-pillar |
| HROW Harrow Health, Inc. | $36.58 | -2.58% | $1.36B | 529-signal |
| AMPH Amphastar Pharmaceuticals, Inc. | $23.54 | +2.17% | $1.04B | 765-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are LJUIF's Key Strengths?
Established brand recognition in China.
- Diverse product portfolio.
- Strong distribution network.
- Stable financial performance with consistent profitability.
What Are LJUIF's Weaknesses?
Heavy reliance on the Chinese market.
- Limited international presence compared to larger competitors.
- Potential vulnerability to regulatory changes in China.
- Dependence on China Pharmaceutical Co., Ltd.
What Could Drive LJUIF Stock Higher?
Potential approval of new pharmaceutical products in China.
- Expansion of distribution network in emerging markets.
- Increasing demand for generic drugs in China.
- Strategic partnerships with other pharmaceutical companies.
- Government support for the pharmaceutical industry in China.
What Are the Key Risks for LJUIF?
Regulatory changes in the pharmaceutical industry in China.
- Intense competition from domestic and international players.
- Price pressures from generic drug manufacturers.
- Product recalls or liability claims.
- Dependence on China Pharmaceutical Co., Ltd.
What Are the Growth Opportunities for LJUIF?
- Expanding market share in China: With China's growing healthcare market, SSY Group has the opportunity to increase its market share by leveraging its established distribution network and brand recognition. The Chinese pharmaceutical market is projected to reach $450 billion by 2030, offering significant growth potential for companies like SSY Group. This expansion can be achieved through strategic partnerships, product innovation, and targeted marketing campaigns.
- Increasing international sales: SSY Group can pursue growth by expanding its sales beyond China. Focusing on emerging markets with unmet healthcare needs presents a significant opportunity. The global market for generic drugs is expected to reach $459.71 billion in 2029, presenting a substantial opportunity for SSY Group to increase its international presence. This expansion requires adapting products to meet local regulatory requirements and establishing distribution channels in new markets.
- Developing new pharmaceutical products: Investing in research and development to create innovative pharmaceutical products can drive future growth. Focusing on areas such as biosimilars and novel drug delivery systems can provide a competitive edge. The global biosimilars market is projected to reach $100 billion by 2030, offering a lucrative opportunity for SSY Group to invest in biosimilar development and capture a share of this growing market.
- Strategic acquisitions and partnerships: SSY Group can accelerate its growth through strategic acquisitions and partnerships with other pharmaceutical companies. Acquiring companies with complementary product portfolios or distribution networks can expand its market reach and product offerings. Forming partnerships with research institutions can enhance its R&D capabilities and accelerate the development of new products.
- Improving operational efficiency: Enhancing operational efficiency can improve profitability and free up resources for investment in growth initiatives. Implementing lean manufacturing principles and optimizing supply chain management can reduce costs and improve productivity. Investing in automation and digitalization can further enhance operational efficiency and improve the company's competitive position.
What Are LJUIF's Competitive Advantages?
- Established presence in the Chinese pharmaceutical market.
- Diverse product portfolio.
- Strong brand recognition under the Shimen brand.
- Subsidiary of China Pharmaceutical Co., Ltd., providing access to resources and expertise.
What Does LJUIF Do?
SSY Group Limited, originally incorporated in 2004 as Lijun International Pharmaceutical (Holding) Co., Ltd., rebranded in May 2015, is an investment holding company engaged in the research, development, manufacture, and sale of pharmaceutical products. Headquartered in Wanchai, Hong Kong, the company primarily serves hospitals and distributors in the People's Republic of China, while also maintaining an international presence. SSY Group's product portfolio is diverse, encompassing intravenous infusion solutions in various formats such as non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottles, as well as ampoule injections, small volume injections, oral preparations, Chinese medicine preparations, and biological preparations. Additionally, the company produces bulk pharmaceutical products and medical materials. Beyond manufacturing, SSY Group is involved in pharmaceutical technology research, development, and consulting, as well as logistics services for pharmaceutical products. The company also has interests in the food, beverage, and catering business. SSY Group operates as a subsidiary of China Pharmaceutical Co., Ltd. and markets its products under the Shimen brand.
What Products and Services Does LJUIF Offer?
- Researches and develops pharmaceutical products.
- Manufactures intravenous infusion solutions in various formats.
- Produces ampoule and small volume injections.
- Offers oral preparations and Chinese medicine preparations.
- Develops and manufactures biological preparations.
- Produces bulk pharmaceutical products and medical materials.
- Provides pharmaceutical technology research, development, and consulting services.
- Offers logistics services for pharmaceutical products.
How Does LJUIF Make Money?
- Develops and manufactures a range of pharmaceutical products.
- Sells products to hospitals and distributors in China and internationally.
- Generates revenue through product sales and related services.
- Invests in research and development to create new products and improve existing ones.
What Industry Does LJUIF Operate In?
SSY Group Limited operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The global pharmaceutical market is experiencing growth driven by aging populations and increasing healthcare expenditure, particularly in emerging markets like China. SSY Group's focus on intravenous infusion solutions and injections positions it within a segment experiencing steady demand. Competitors include both domestic Chinese manufacturers and international players. The company's success hinges on its ability to navigate regulatory hurdles, maintain product quality, and expand its market reach.
Who Are LJUIF's Key Customers?
- Hospitals in China
- Pharmaceutical distributors in China
- International distributors
- Healthcare providers
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in HKD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 43 |
| 2026-08-26 | 43 |
| 2026-08-29 | 43 |
| 2026-09-01 | 43 |
| 2026-09-04 | 43 |
| 2026-09-07 | 43 |
| 2026-09-10 | 43 |
What changed?
The score has stayed at 43.
Over the same 18 days the stock moved +0.0%.
Company Profile
SSY Group Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO Ji Guang Qu. LJUIF has traded publicly since 2015.
SSY Group Limited Financial Trajectory
SSY Group Limited (LJUIF) reported $300.9M in revenue for Q2 FY2026, reflecting 17.0% growth compared to the prior quarter. The company recorded net income of $40.8M, with diluted EPS of $0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, LJUIF averaged $0.01 in diluted EPS.
How SSY Group Limited Is Valued
SSY Group Limited carries a market capitalization of $1.19B, placing it in the small-cap category.
Key Financial Metrics
Return on equity for SSY Group Limited stands at 6.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.7%, showing how much profit it generates from its asset base. LJUIF trades at a trailing price-to-earnings ratio of 15.05, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
SSY Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.28 places it in the grey zone, a middle ground that warrants monitoring.
LJUIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established brand recognition in China.
- Diverse product portfolio.
- Strong distribution network.
- Stable financial performance with consistent profitability.
Bear Case
- Heavy reliance on the Chinese market.
- Limited international presence compared to larger competitors.
- Potential vulnerability to regulatory changes in China.
- Dependence on China Pharmaceutical Co., Ltd.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $301M | $41M | $0.01 |
| Q4 FY2025 | $257M | $24M | $0.01 |
| Q2 FY2025 | $274M | $36M | $0.01 |
| Q4 FY2024 | $310M | $48M | $0.02 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from HKD at today's rate
LJUIF Latest News
-
Asian Penny Stocks Spotlight: SSY Group And 2 Promising Picks
Yahoo! Finance: LJUIF News · Jan 6, 2026
-
Asian Penny Stocks To Watch In November 2025
Yahoo! Finance: LJUIF News · Nov 11, 2025
-
Stocks That Hit 52-Week Highs On Friday
· Jan 31, 2020
LJUIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LJUIF.
Price Targets
Wall Street price target analysis for LJUIF.
LJUIF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LJUIF; grades run from A+ (80-100) to F (below 30).
Leadership: Jiguang Qu
CEO
Jiguang Qu serves as the CEO of SSY Group Limited, overseeing the company's strategic direction and operational performance. His background includes extensive experience in the pharmaceutical industry, with a focus on manufacturing and distribution. Prior to joining SSY Group, Mr. Qu held leadership positions at various pharmaceutical companies in China, where he was responsible for driving growth and improving operational efficiency. He holds a degree in Pharmaceutical Sciences and an MBA from a leading business school.
Track Record: Under Jiguang Qu's leadership, SSY Group Limited has expanded its product portfolio and strengthened its market position in China. He has overseen the successful launch of several new products and implemented initiatives to improve operational efficiency and reduce costs. Mr. Qu has also focused on expanding the company's international presence and building strategic partnerships with other pharmaceutical companies.
LJUIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that SSY Group Limited may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in exiting positions.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- Limited access to company information and management.
- Increased risk of delisting or going dark.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Subsidiary of China Pharmaceutical Co., Ltd.
- Operating history since 2004.
- Presence in the pharmaceutical industry.
- Employee count of 6146 suggests a substantial operation.
- Shimen brand recognition.
LJUIF Healthcare Stock FAQ
Is LJUIF a good stock?
Stock Expert AI does not rate LJUIF buy, sell or hold. SSY Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about LJUIF stock?
Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key metrics to consider include the company's P/E ratio of 15.05, profit margin of 14.4%, and dividend yield of 5.75%.
What are the key factors to evaluate for LJUIF?
Evaluate LJUIF on fundamentals, analyst consensus, and risk factors. P/E: 15.05x vs the S&P 500's ~20-25x. A dividend yield of 5.75% offers an attractive income stream for investors. Not financial advice.
How frequently does LJUIF data refresh on this page?
LJUIF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LJUIF's recent stock price performance?
SSY Group Limited (LJUIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LJUIF overvalued or undervalued right now?
SSY Group Limited (LJUIF) trades at 15.05x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of LJUIF?
Yes, most major brokerages offer fractional shares of SSY Group Limited (LJUIF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track LJUIF's earnings and financial reports?
SSY Group Limited (LJUIF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for LJUIF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or delayed.